Have a personal or library account? Click to login
Individualized Physiotherapy of Upper Body Functional Movement Disorder – Two Illustrative Cases Cover

Individualized Physiotherapy of Upper Body Functional Movement Disorder – Two Illustrative Cases

Open Access
|Jun 2024

Full Article

Introduction

Functional neurological disorders are common and multiple neurological professions are engaged in their management [1]. One of the largest subgroups of functional neurological disorders are motor/movement disorders. Despite their great heterogeneity, they are all characterized by inconsistency in severity and phenomenology under attentional refocusing. As a second diagnostic pillar incongruency to other non-functional movement disorders and neuroanatomical rules has been proposed. However, there is an intensive discussion whether this term should be avoided, as it might just be another way of making a diagnose of exclusion and requires omniscience in clinical neurology [2]. Unfortunately, many patients are undiagnosed or have long diagnostic delays and thus receive no or delayed therapy, which is mostly unspecific [1]. Based on the biopsychosocial model, functional movement disorders are multifactorial in origin, which makes it essential for the specific physiotherapy to identify individual factors. Predisposing vulnerabilities, e.g. in the biological context of an “organic” disease, in the sense of an emotional disorder on a psychological level, or in the social context of a specific life event or difficulty. Precipitation mechanisms, e.g. in the biological context of a physical injury/pain or e.g. in the psychological context of a life event perceived as negative and unexpected. Perpetuating factors are described in the biological context as plasticity in the motor and sensory pathways of the CNS leading to habitual abnormal movements and deconditioning, or in the psychological context as abnormal perceptions of illness [3]. These factors influence the development and progression of the disorder and their processing helps to design a comprehensive and individualized therapy together with the patient. Therefore, specific physiotherapy follows a cognitive behavioral approach and differs from conventional neurological therapy concepts [3]. Of note, specifically targeted physiotherapy is considered a first-line treatment [4, 3, 5] and greatly differs from conventional physiotherapy concepts for neurological diseases [1]. However, only a few studies [3, 6, 7, 8] provided information on specific symptoms, e.g., functional tremor [7], but detailed descriptions and practical or real-world applications for the physiotherapeutic treatment of functional movement/motor disorders that go beyond functional gait disorders or affect the upper body are mostly missing.

For this reason, we here describe two illustrative cases demonstrating the applicability of previous findings and their adaptation to functional disorders other than gait disorders.

Case Settings

Based on two illustrative cases, we demonstrate how specific physiotherapy can be practically applied in an outpatient setting for patients with functional movement disorders of the face and upper body. Patients received between 10 and 20 treatment sessions, each lasting approximately 60 minutes. Core elements of the specific physiotherapy were adapted from consensus recommendations [3] and included 1) psychoeducation about the clinical picture to promote its acceptance and understanding, 2) redirecting attention to foster movement (re)learning by promoting automated movements and 3) establishing awareness of self-efficacy of symptom reduction. A detailed summary of the clinical and therapeutic characteristics of both patients is given in Table 1.

Table 1

Clinical and therapeutic characteristics of patients.

CLINICAL AND THERAPEUTIC CHARACTERISTICS OF PATIENTSCASE 1CASE 2
Main symptoms
  • Weakness of eyelid opening

  • Perioral jerks

  • Postural and intention tremor left arm

Secondary symptoms
  • Fatigue

  • Fatigue

  • Pain in neck, shoulders

Work
  • Unable to work 6 months before her first therapy session at the age of 20

  • Receiving disability pension since the age of 55

Age at onset
  • 19

  • 52

Age at diagnosis
  • 20

  • 55

Age at intervention
  • 21

  • 58

Previous treatment
  • Physiotherapy with craniosacral therapy

  • Botulinum neurotoxin i.m. injections

  • Manual therapy with massages of neck muscles

Individualized movement treatment with specific individualized modalities/stimuli
  • Personal preference and interest in learning to juggle, e.g., gamification

  • Refocusing of attention away from eyelid closure towards autonomic driven function with juggle

  • Personal key moment by recognizing the function in the video feedback

  • Motivated and informed to practice a home exercise training

  • Reflexion of everyday life

  • Recognition of the symptom triggers and their dependence

  • Personal key moment when recognizing the reversibility of the symptoms

  • Focus on directed attention with haptic and auditive stimulus e.g., texture of the knife handle when cutting, listening the bubbles when drinking, rhythmic foot tapping

  • Building self-confidence through symptom control, being back to society

Goals pre-treatment
  • Voluntarily opening eyes:

    10 min. sports

    1–2 hrs. riding horse

    1–2 hrs. computer work

  • Cooking, cutting vegetables without symptoms

  • Reviving social activities

Goals post-treatment
  • 2–3 times per week fitness

  • Functioning at work

  • Attending concerts, exhibitions with more self-confidence and trust

Case 1 «Eyes on the juggle»

Background

A 21-year-old woman presented with weakness of eyelid opening and perioral jerks (Video 1a) since the age of 19 years. The diagnosis of a functional movement disorder was made at the age of 20 years. Before commencing specific physiotherapy, she was on sick leave from her job as a hearing aid acoustician for six months. She also stopped doing sports (fitness and yoga) as this had caused worsening of symptoms. Only during horse riding, an improvement of eyelid opening was observed by friends, which, however, was not perceived by the patient herself.

Video 1a

Pre-intervention. 1b: Start schematic juggling (in front of a mirror). 1c: Key moment during physiotherapy (in front of a mirror). 1d: Progression in juggling. 1e: Post-intervention.

Intervention

At the start of therapy, the patient defined her primary treatment goal as voluntary opening and controlling of her eye movements especially during sports activities and computer work. She was instructed about the clinical picture and possible improvement using the example of horse riding, which improved symptoms by redirecting attention. In a next step, we introduced juggling to the patient, which she always wanted to learn. Through its motivating, playful character it very efficiently redirected her attention away from the affected body regions (eyes, mouth). Initially, a schematic structure of juggling was instructed, e.g., throwing and catching one ball per hand and throwing from one side to the other (Video 1b). Juggling was performed in front of a mirror and videotaped, so the patient received direct visual feedback. Recognizing that she could reduce her symptoms by directing attention towards catching the ball was perceived as a key moment, i.e., as if she “flipped a switch in her head” and she felt empowered (Video 1c). In addition to her physiotherapy sessions twice a week, she practiced two times per week by herself. In the third week of treatment, she was symptom-free. From then on, she could manage her private and professional life without symptoms. Next, we gradually made juggling more difficult, e.g., using three balls, or juggling while standing on a wobble board, until the end of therapy (Video 1d & 1e).

In addition, we encouraged the patient to identify perpetuating factors, e.g., her working conditions. Thus, additional relaxation strategies such as grounding [5] and pacing [3] were practised. After further improvement of her performance and increasing confidence, the patient decided to resume her professional work and initiated regular fitness training and yoga in addition to her hobby of horse riding.

More than a year after the end of treatment, the patient is still symptom-free. She identified her stressful working condition as a disease perpetuating factor. Thus, she changed her job and recently started working as a horse caretaker.

Case 2 «Back to society with touch and hearing»

Background

A 58-year-old woman was suffering for six years from postural and intention tremor of the left hand. The tremor was accompanied by fatigue and pain in the neck and shoulders. She quit her job, had difficulties performing household activities and could no longer pursue hobbies. The tremor increased with conscious use of the arm or when trying to supress it (Video 2a). She realized that routine tasks not requiring much attention, e.g., cleaning herself in the bathroom, sometimes considerably ameliorated the tremor. Due to the variability of the symptoms and their rapid change she felt insecure during activities. Moreover, she had difficulty explaining her symptoms to her family and friends, which resulted in loss of social contact.

Video 2a

Pre-intervention. 2b. Key moment during physiotherapy. 2c. Post-intervention.

Intervention

In the first sessions, the understanding of the clinical picture, its therapy, and the importance of conscious control of attention were discussed. The above-mentioned examples from everyday life were used to illustrate the attention dependency of symptoms and their variability. The patient quickly recognised additional triggering factors such as crowds and the associated inner expectation that “nothing will work anymore”. Together we defined therapy goals as reducing the tremor during cooking and eating and being able to meet family and friends again. During the first treatment sessions, the patient realized that her tremor decreased when she focused attention on the texture of objects she was using, e.g., the perception of the texture of a cup when drinking or the handle of a knife when chopping. Sounds the patient could focus on when moving her arm were also helpful, e.g., her tremor decreased while concentrating on the sounds of the bubbles when drinking sparkling water. Focusing on rhythmic motor performance, for example when tapping her foot on the ground, was also helpful to gain control of her arm movements (Video 2b & 2c). The patient’s own perception of the change was supported by video feedback to visualize the reversibility of symptoms. This was perceived as a key moment. Her self-confidence grew and she started to incorporate techniques she had learned into her daily life, e.g., while attending concerts and family celebrations. Moreover, she used the knowledge she gained about the disease to explain her symptoms to family members and friends, which had previously hindered her from meeting them.

Six months after the treatment, the patient was able to willingly control her tremor, even though the symptoms persisted in her daily life. It seemed that the patient only used her treatment strategies, when necessary, i.e., when the tremor appeared. Meaning that these strategies are used more as compensation rather than a consistent learning method to adapt motor control. At the same time, from the authors’ perspective, this suggests an incomplete understanding of the illness and its therapy, as there was also a lack of engagement with potential disease-perpetuating factors in her daily life.

Discussion

Our case series demonstrate that disease-specific physiotherapy in an outpatient setting is feasible and effective in patients with various functional movement disorders of the face and upper body. Such treatment differs from conventional physiotherapy applied for non-functional neurological disorders, with its core element being not to focus on dysfunction/ affected limbs. Thus, manual therapy or strength training, focussing on movement execution and control of the affected body region, are inefficient and can instead maintain and even worsen symptoms [3]. In contrast, physiotherapy for functional movement disorders educates patients to control and redirect attention away from the symptomatic body part, thus reducing excessive pathological extrinsic control and fostering more automatic, intrinsic movements [3, 5, 4]. For this purpose, at the beginning of our training, we analysed which stimulus quality, e.g., acoustic, tactile, or visual, helped the individual patient best to redirect her attention easily and effectively away from the symptomatic body region.

Moreover, our treatment comprised psychoeducation. We enabled the patients to realize that there are certain mechanisms in their daily life that alleviated their symptoms (e.g., hobbies) and included them in our treatment. Therefore, interests and personal preferences should be integrated into treatment sessions when designing individual therapeutic strategies. With the help of visual feedback (e.g., mirror, video), patients experienced their agency, which increased their self-confidence and encouraged them to increase their training level, i.e., trying out new motor tasks. Patients reported key moments resembling turning points in coping with the disease. Importantly, patients described that our training not only reduced motor symptoms but also had, albeit less so, positive effects on fatigue, mood, concentration, and pain.

It is important to keep in mind that in our experience patients with functional movement disorders tend to over-perform once they notice symptom reduction. Newly gained control of action can lead to increased expectations, pressure, and stress, which in turn can result in relapses. In such situations focussing on psychoeducation is very helpful. Thus, the physiotherapist can enable the patient to identify disease mechanisms that might have contributed to the current symptom exacerbation and ensure that the patient fully understood the disease and its perpetuating factors. Moreover, including pacing, graded exercise, and relaxation strategies can help to better cope with psychological stressors [3, 5, 6, 9].

Another aspect for relapse of symptoms could be that stimuli and training techniques became too trivial to effectively capture attention and require adaptation to keep the attention span high enough. Thus, a gradual increase of performance difficulty is recommended.

Our case series resemble two different responses to specialized physiotherapeutic treatment. The first patient totally recovered from symptoms whereas the second one used the treatment to temporarily suppress her symptoms. Thus, the latter patient continued to have symptoms especially when confronted with disease-triggering factors during her daily life. It emphasizes that a central understanding and acceptance of the illness and its therapy are key mechanisms to achieve consistent symptom relief. Therefore, it is crucial to facilitate interdisciplinary exchanges with other disciplines involved in the treatment of the same patient. It is highly recommended to ensure a uniform treatment according to the same guidelines. A broad range of information and training for therapists and other healthcare professionals is needed to raise awareness of functional neurological disorders and to establish nationwide therapeutic services.

Financial Disclosures for the previous 12 month

Christof Degen-Plöger

Stock Ownership in medically related fieldsChristof Degen-Plöger has no stock ownership in medically related fields
Intellectual Property RightsChristof Degen-Plöger has no intellectual property rights
ConsultanciesChristof Degen-Plöger has no consultancies
Expert TestimonyChristof Degen-Plöger has no function as an expert testimony
Advisory BoardsChristof Degen-Plöger is not a member of any advisory board
EmploymentUniversity Medical Center Schleswig-Holstein, Campus Lübeck
PartnershipsChristof Degen-Plöger does not enter partnerships
InventionsChristof Degen-Plöger has no inventions
ContractsChristof Degen-Plöger has no contracts
HonorariaChristof Degen-Plöger does not receive any honoraria
RoyaltiesChristof Degen-Plöger receives no royalties
PatentsChristof Degen-Plöger owns no patents
GrantsChristof Degen-Plöger does not receive any grants
OtherChristof Degen-Plöger declare that there are no additional disclosures to report

Annemarie Reincke

Stock Ownership in medically related fieldsAnnemarie Reincke has no stock ownership in medically related fields
Intellectual Property RightsAnnemarie Reincke has no intellectual property rights
ConsultanciesAnnemarie Reincke has no consultancies
Expert TestimonyAnnemarie Reincke has no function as an expert testimony
Advisory BoardsAnnemarie Reincke is not a member of any advisory board
EmploymentUniversity Medical Center Schleswig-Holstein, Campus Kiel
PartnershipsAnnemarie Reincke does not enter partnerships
InventionsAnnemarie Reincke has no inventions
ContractsAnnemarie Reincke has no contracts
HonorariaAnnemarie Reincke does not receive any honoraria
RoyaltiesAnnemarie Reincke receives no royalties
PatentsAnnemarie Reincke owns no patents
GrantsAnnemarie Reincke does not receive any grants
OtherAnnemarie Reincke declares that there are no additional disclosures to report

Christina Bolte

Stock Ownership in medically related fieldsChristina Bolte has no stock ownership in medically related fields
Intellectual Property RightsChristina Bolte has no intellectual property rights
ConsultanciesChristina Bolte has no consultancies
Expert TestimonyChristina Bolte has no function as an expert testimony
Advisory BoardsChristina Bolte is not a member of any advisory board
EmploymentUniversity Medical Center Schleswig-Holstein, Campus Lübeck
PartnershipsChristina Bolte does not enter partnerships
InventionsChristina Bolte has no inventions
ContractsChristina Bolte has no contracts
HonorariaChristina Bolte does not receive any honoraria
RoyaltiesChristina Bolte receives no royalties
PatentsChristina Bolte owns no patents
GrantsChristina Bolte does not receive any grants
OtherChristina Bolte declares that there are no additional disclosures to report

Carl Alexander Gless

Stock Ownership in medically related fieldsCarl Alexander Gless has no stock ownership in medically related fields
Intellectual Property RightsCarl Alexander Gless has no intellectual property rights
ConsultanciesCarl Alexander Gless has no consultancies
Expert TestimonyCarl Alexander Gless has no function as an expert testimony
Advisory BoardsCarl Alexnader Gless is not a member of any advisory board
EmploymentUniversity Medical Center Schleswig-Holstein, Campus Kiel
PartnershipsCarl Alexander Gless does not enter partnerships
InventionsCarl Alexander Gless has no inventions
ContractsCarl Alexander Gless has no contracts
HonorariaCarls Alexander Gless does not receive any honoraria
RoyaltiesCarl Alexander Gless receives no royalties
PatentsCarl Alexander Gless owns no patents
GrantsCarl Alexander Gless does not receive any grants
OtherCarl Alexander Gless has been supported by the Faculty of Medicine, University of Kiel, Germany.

Kerstin Lüdtke

Stock Ownership in medically related fieldsKerstin Lüdtke has no stock ownership in medically related fields
Intellectual Property RightsKerstin Lüdtke has no intellectual property rights
ConsultanciesKerstin Lüdtke has no consultancies
Expert TestimonyKerstin Lüdtke has no function as an expert testimony
Advisory BoardsKerstin Lüdtke is not a member of any advisory board
EmploymentUniversity of Lübeck
PartnershipsKerstin Lüdtke does not enter partnerships
InventionsKerstin Lüdtke has no inventions
ContractsKerstin Lüdtke has no contracts
HonorariaKerstin Lüdtke reports honoraria from Novartis Pharma for Migraine Workshops (€1500)
RoyaltiesKerstin Lüdtke receives no royalties
PatentsKerstin Lüdtke owns no patents
GrantsKerstin Lüdtke declare grants from Versorgungssicherungsfond for migraine app development (€370.000 for 2023–20205)
OtherKerstin Lüdtke declare that there are no additional disclosures to report

Alexander Münchau

Stock Ownership in medically related fieldsAlexander Münchau has no stock ownership in medically related fields
ConsultanciesAlexander Münchau has consultancies for PTC Therapeutics
Advisory BoardsAlexander Münchau is on advisory board for German Tourette syndrome Association and Alliance of patients with chronic rare diseases
PartnershipsAlexander Münchau does not enter partnerships
InventionsAlexander Münchau has no inventions
HonorariaAlexander Münchau reports honoraria from Desitin, Teva and Takeda
GrantsAlexander Münchau declare support from Foundations: Possehl-Stiftung (Lübeck, Germany), Margot und Jürgen Wessel Stiftung (Lübeck, Germany), Tourette Syndrome Association (Germany), Interessenverband Tourette Syndrom (Germany), CHDI, Damp-Stiftung (Kiel, Germany);
Academic research support: Deutsche Forschungsgemeinschaft (DFG): projects 1692/3-1, 4-1, SFB 936, and FOR 2698 (project numbers 396914663, 396577296, 396474989); European Reference Network – Rare Neurological Diseases (ERN – RND; Project ID No 739510)
Intellectual Property RightsAlexander Münchau has no intellectual property rights
Expert TestimonyAlexander Münchau has no function as an expert testimony
EmploymentUniversity of Lübeck; University Medical Center Schleswig-Holstein, Campus Lübeck
ContractsAlexander Münchau has no contracts
RoyaltiesAlexander Münchau reports royalties for the book Neurogenetics (Oxford University Press)
PatentsAlexander Münchau owns no patents
OtherAlexander Münchau declare commercial research support from: Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion

Kirsten E. Zeuner

Stock Ownership in medically related fieldsKirsten E. Zeuner has no stock ownership in medically related fields
Intellectual Property RightsKirsten E. Zeuner has no intellectual property rights
ConsultanciesKirsten E. Zeuner has served as a consultant and received fees from Ipsen, Alexion, Zambon and the German Federal Institute for Drugs and Medical Devices (BfArM).
Expert TestimonyKirsten E. Zeuner has no function as an expert testimony
Advisory BoardsKirsten E. Zeuner has served on advisory boards for Ipsen, AbbVie, Bial, Alexion, Merz
EmploymentKirsten E. Zeuner is an employee of the University Medical Center Schleswig Holstein, Campus Kiel
PartnershipsKirsten E. Zeuner does not enter partnerships
InventionsKirsten E. Zeuner has no inventions
ContractsKirsten E. Zeuner has no contracts
HonorariaKirsten E. Zeuner reports speaker’s honoraria from Bayer Vital GmbH, BIAL, Alexion, AbbVie and Merz outside the submitted work
RoyaltiesKirsten E. Zeuner receives no royalties
PatentsKirsten E. Zeuner owns no patents
GrantsKirsten E. Zeuner has received research support from the Christa and Hans-Peter Thomsen Foundation, the German Research Foundation (DFG 5919/4-1) and from Strathmann GmbH & Co. KG.
OtherKirsten E. Zeuner declares that there are no additional disclosures to report

Anne Weissbach

Stock Ownership in medically related fieldsAnne Weissbach has no stock ownership in medically related fields
Intellectual Property RightsAnne Weissbach has no intellectual property rights
ConsultanciesAnne Weissbach has no consultancies
Expert TestimonyAnne Weissbach has no function as an expert testimony
Advisory BoardsAnne Weissbach is not a member of any advisory board
EmploymentUniversity Medical Center Schleswig-Holstein, Campus Lübeck
PartnershipsAnne Weissbach does not enter partnerships
InventionsAnne Weissbach has no inventions
ContractsAnne Weissbach has no contracts
HonorariaAnne Weissbach does not receive any honoraria
RoyaltiesAnne Weissbach receives no royalties
PatentsAnne Weissbach owns no patents
GrantsAnne Weissbach declares grants from: German Research Foundation (DFG, WE5919/2-1, WE 5919/4-1, and FOR2698/2), the Dystonia Medical Research Foundation, and an Edmond J. Safra Career Development Award from the Michael J. Fox foundation (MJFF-022062)
OtherAnne Weissbach declares that there are no additional disclosures to report

Ethics and Consent

Approval of the local ethic committee of the University of Lübeck, Germany was obtained for the study (22-008). Informed consent of all patients was obtained prior to inclusion of the study. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Information

This work was support by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, WE5919/4-1).

Competing Interests

The authors have no competing interests to declare.

Author Contributions

  1. Research project: A) Conception, B) Organization, C) Execution.

  2. Manuscript Preparation: A) Writing of the first draft, B) Review and Critique.

Author 1 Christof Degen-Plöger: 1A, 1B, 1C, 2A

Author 2 Annemarie Reincke: 1A, 1B, 2B

Author 3 Christina Bolte: 1A, 1B, 1C, 2B

Author 4 Carl Alexander Gless: 1A, 2B

Author 5 Kerstin Lüdtke: 1A, 2B

Author 6 Alexander Münchau: 2B

Author 7 Kirsten E. Zeuner: 1A, 2B

Author 8 Anne Weissbach: 1A; 1B, 1C, 2B

DOI: https://doi.org/10.5334/tohm.895 | Journal eISSN: 2160-8288
Language: English
Submitted on: Apr 1, 2024
|
Accepted on: Apr 1, 2024
|
Published on: Jun 28, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2024 Christof Degen-Plöger, Annemarie Reincke, Christina Bolte, Carl Alexander Gless, Kerstin Luedtke, Alexander Münchau, Kirsten E. Zeuner, Anne Weissbach, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.